{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.2","upperLimit":"18.3","value":"11.1"},{"groupId":"OG001","lowerLimit":"7.7","upperLimit":"11.0","value":"9.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"160"},{"groupId":"OG001","value":"159"}],"units":"Participants"}],"description":"Duration of response is defined only for subjects demonstrating a response (eg, CR, CRi, PR, PRwL), with the response and progression statuses both determined by the blinded, central independent review. The analysis will be descriptive for each treatment group only.","dispersionType":"95% Confidence Interval","groups":[{"description":"Duvelisib is administered orally and supplied as 5 mg and 25 mg formulated capsules.","id":"OG000","title":"Duvelisib"},{"description":"Ofatumumab is administered as an IV infusion and is supplied in single-use vials at two strengths, 100 mg/5 mL and 1000 mg/50 mL.","id":"OG001","title":"Ofatumumab"}],"paramType":"MEDIAN","populationDescription":"Intent to Treat","reportingStatus":"POSTED","timeFrame":"Time from the first documentation of response to first documentation of progressive disease or death due to any cause","title":"Duration of Response (DOR)","type":"SECONDARY","unitOfMeasure":"Months"}